At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
01672 ASCLETIS-B
Trading 04-29 15:36:49
6.660
+0.480
+7.77%
High6.800
Low6.100
Vol3.39M
Open6.280
D1 Closing6.180
Amplitude11.33%
Mkt Cap6.41B
Tradable Cap6.41B
Total Shares963.00M
T/O22.18M
T/O Rate0.35%
Tradable Shares963.00M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Loading ...
Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
Ascletis Announces Positive Topline Results of U.S. Phase Ib Multiple Ascending Dose Study of Small Molecule Oral Glp-1R Agonist Asc30 and Submission of 13-Week Phase Iia Study Protocol to FDA
BRIEF-Ascletis Announces Positive Interim Results from Its U.S. Phase Ib Trial with ASC30, a Potentially First-in-Class Subcutaneous Injection Small Molecule GLP-1R Agonist
Ascletis Announces Positive Interim Results From Its U.S. Phase Ib Trial With Asc30, a Potentially First-in-Class Subcutaneous Injection Small Molecule Glp-1R Agonist
Ascletis Announces Positive Interim Results From First Two Cohorts of U.S. Phase Ib Multiple Ascending Dose Study of Small Molecule Oral Glp-1R Agonist Asc30
Ascletis Announces Positive Results From U.S. Phase Ia Single Ascending Dose Study of Small Molecule Oral Glp-1R Agonist Asc30 and Provides Program Update
Ascletis Pharma Inc is a China-based investment holding company principally engaged in the research, development, production, marketing and sales of pharmaceutical products. The Company mainly focuses on viral diseases, non-alcoholic steatohepatitis (NASH) and oncology fields. Viral diseases pipeline includes Ritonavir, Ravidasvir, Danoprevir and others. NASH pipeline includes ASC40, ASC41, ASC42 and others. Oncology pipeline includes ASC60, ASC61 and others.